Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides allergen immunotherapy + lepidoglyphus allergen immunotherapy
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Dermatophagoides allergen immunotherapy + Lepidoglyphus allergen immunotherapy is a subcutaneous allergen immunotherapy (SCIT) product developed by Inmunotek S.L. It is composed of glutaraldehyde-modified (polymerized/allergoid) extracts from house dust mites (*Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*) and the storage mite *Lepidoglyphus destructor*. The polymerization process reduces the IgE-binding capacity (allergenicity) while preserving the ability to induce a protective immune response (immunogenicity), thereby improving safety and allowing for faster up-dosing. The therapy is indicated for patients with moderate-to-severe allergic rhinitis or rhinoconjunctivitis, with or without mild-to-moderate controlled asthma, who are sensitized to these specific mite species. It is currently being evaluated in Phase III clinical trials to confirm its efficacy in inducing allergen-specific immune tolerance.
- Other names
- Dermatophagoides/Lepidoglyphus allergen immunotherapy
02
Targets
TLR4 (Toll-like receptor 4)MHC II (Major histocompatibility complex class II receptor)BCR (Immunoglobulin G B Cell Receptor)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on dermatophagoides allergen immunotherapy + lepidoglyphus allergen immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides allergen immunotherapy + lepidoglyphus allergen immunotherapy.